Aegis Capital Maintains NephroGenex (NRX) at 'Buy'; Pyridorin Safe in QT/QTc Study
Tweet Send to a Friend
Aegis Capital affirms NephroGenex (Nasdaq: NRX) at Buy with a price target of $15 following news that a thorough QT/QTc ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
